Mirataz™ is a transdermal ointment containing mirtazapine. It is the first FDA-approved transdermal medication for the management of weight loss in cats.
- In clinical studies, Mirataz resulted in significant weight gain in cats in as little as 14 days following topical application of 2mg per day
- Gives clients a practical way to manage their cat's weight loss without administration of oral medication and does not rely on the cat to eat to be medicated
- Mirataz achieves measurable plasma concentrations of mirtazapine in cats using proprietary Accusorb™ technology.
- Well tolerated both locally and systemically in clinical studies
- View the detailed product information for more detailed information and study reference
NEW extended shelf life of 48 months!